Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

NCT01063829 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

HCMV Reactivation or HCMV End-Organ Disease

Interventions

DRUG: 60 mg AIC246
DRUG: 120 mg AIC246
DRUG: 240 mg AIC246
OTHER: Placebo

Sponsor

AiCuris Anti-infective Cures AG

Collaborators

[object Object]